Business / Technology

Add as a preferred source on Google

Isomorphic Labs Raises $5 Billion to Advance AI Drug Programs

Greenoaks and Sequoia Capital co-led the round. The company also reported positive preclinical results in internal oncology and immunology programs.

Updated 2 min read
A technician handles samples beside cell-culture trays in a London biomedical laboratory. / EconoTimes.ai (mono)
A technician handles samples beside cell-culture trays in a London biomedical laboratory. / EconoTimes.ai (mono)

Isomorphic Labs has raised $5 billion in a Series C to scale its AI drug-design work and prepare its earliest treatment programs for clinical testing, while building the capacity to develop them.

Greenoaks and Sequoia Capital co-led the financing. Andreessen Horowitz, also known as a16z, and other new investors joined the round. Alphabet made what Isomorphic described as a continued significant investment, and all existing investors participated. They include the UK Sovereign AI Fund, Temasek, CapitalG, GV, Thrive Capital and MGX.

The London-based company plans to use the funding for further work on its drug-design engine, IsoDDE, and research in more areas of biology. The proceeds will also support in-house and partner programs, along with infrastructure for translational and clinical development. Isomorphic was established in 2021 and emerged from Google DeepMind.

Isomorphic said its internal oncology and immunology programs had positive preclinical results. It also reported positive preclinical results in partner programs. The announcement did not name drug candidates, provide detailed preclinical data or set a date for clinical entry.

The company did not disclose a valuation, investor-by-investor contributions or ownership terms. Bloomberg reported Nov. 4, citing people familiar with the discussions, that talks had involved a possible valuation near $50 billion. Isomorphic did not confirm that figure in its Nov. 17 announcement. EconoTimes previously covered the funding discussions.

The Series C follows a $2.1 billion Series B announced May 12 and led by Thrive Capital. The latest announcement did not provide a timetable for the company’s next clinical-development milestone.

Related articles

View all